To date, there have been few prospective assessments investigating HRQOL and skin toxicity.15 In addition, the previous analyses that have evaluated skin toxicity have not examined the association between HRQOL and all other AEs, including severe symptoms mostly caused by the concomitant chemotherapies.15, 16, 17, 18, 19 In this respect, a comprehensive examination of the adverse effect on HRQOL is needed to clarify the proper use of anti‐EGFR ab together with the standard chemotherapy for mCRC patients with RAS wild‐type tumors. Here, EGFR is linked to dermatological toxicity.